George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The announcement today that thousands of people will be screened for lung cancer by NHs made me rush to check my shares here. Only to find it seems that they’ll use a different system than Onc’s
Ah well. How long to wait until I get my investment back, if ever?
The strategic messaging has lacked clarity and numbers have been fluffy. Share price has tumbled and clearly major investors have stepped in together with the board to force change. I think it is good news, but whether it's totally fair or not is a different discussion. As I have said before, they can do around 35k samples in the German lab, pretty much at no increased cost and with margins 75% plus.
This business has a unique, value adding IP and this is now ONLY about selling, selling and selling, The future is bright and this is a rock bottom valuation. It could go lower, but eventually it will bounce as the sample numbers go up + top line will pretty much go straight to the bottom line. I am just drip adding, with no idea where the bottom is, but I know whatever I do helps getting my average down and will be a good deal in due course.
what's your deal c_schmitt. your reactions resemble a spasm.....
it's obvious you are frustrated. if you can't see anything good about onc, then sell your shares or be smart and don't act like a pre-puberty teenager. i am not that old but you seem a bit immature.
i dread to know what you were like in 2007/08 or during the covid crunch time..... absolutely no resilience. i would assume that my steak here is way heavier and my losses way bigger than yours.
yea i want people to see the value of onc, don't you? if anyone is playing a dirty game it might be you.
the board is making decisions and they are replacing the ceo with immediate effect. this is a result of the recent performance mot likely. but if you think adam had no impact on the success of onc, establishing a service offering that is ready to make money and laying foundations to realise growth moving forward, you are wrong. i am excited for what is to come. let this flower grow man. stop ****ting all over it.
'Thank you, Adam for your service to ONC over the last 5 years.' LOL
'Speaking as an outsider' LOL
Thank you, Adam for your service to ONC over the last 5 years. Speaking as an outsider, I am cautious to make judgements but the macro-environment has been challenging and at times also provided tailwinds. Regardless, I could see the hard work and struggle to get ONC to where we are now, irrespective of SP. Not everything worked out, clearly. But it seems the company after the restructure and asset sale is now at a new Ground 0. A fresh start...let's just imagine it's all beginning now.
Glad to read Alistair's comments around new and focused growth strategy for FY24 - keen to learn what that may be in detail. Expanding US Commercial team further and promising realisatuon of shareholder value and enhancing dialogue/ in my interpretation being kore Shareholder focused. A more business minded approach is much needed here.
Back to basics. We have a company here with high calibre medical experts, proven business executives and high value commercial teams and not to forget the scientists delivering the work!
Let's try and be more financially responsible moving forward. Feel slightly better now although it was indicated that this financial year is tough. So I guess we are in for a shocker when the next results are out summing up the first year in the new fiscal cycle. If it dips further as a result I take any scraps I have left to put down here. I mean, it doesn't take much right now to lower my average significantly at these values.
Immunoinsights is supposed to be the 'Jewel in the crown'.
As Rathgar noted CDT Lung sold for £13M cash yet the current mcap is now around £12M.
I asked Adam moons ago if he thought the 'expensive' US sales guys wages could be justified and he said he had no concerns they would earn their money.
Something is not looking good.
I think Adam needs to setup an interview with Paul Hill (V O X) and give a more detailed view of how he sees things going with what is left of the Business.
Hi Adam, a follow up question please as I invested at the time of your fund raise at £1.80/share and have held shares since this time so hopefully we are now at the floor in terms of how the Company is valued and that we will see enhanced value recognised by the market in the coming months.
Oncimmune has progressively focused its corporate strategy on the development and growth of its pharma services offering through the ImmunoINSIGHTS business. You have sold the Oncimmune's EarlyCDT® Lung product, EarlyCDT® platform and autoantibody development business for £13M so my question is what is the value of the ImmunoINSIGHTS business - and projected revenues to the year end given existing Pharma clients, pipeline of new sales ( from your investment is a much larger sales force) and the ongoing annual contract of £1.14M from Freenome. Many thanks.
Hi Adam, I was one of the people who bought Oncimmune at the time of the fund raise at £1.80/share and attended one of the presentations with your team. I have remained loyal to ONC throughout and the recent challenges, can you please share what the business hopes to achieve between now and the year. You talk about have relationships and contracts with 7 large pharma customers already in place, you have increased the size of the sales force, how can you address the issue of getting the samples back so you can realise increased revenues and improve the bottom line. thanks, Keith
I agree Rooster, communication really needs to be improved; both in terms of communication of strategic intent, ambition and results. The latter needs to be more frequent and much more crisp.
However, I am also positive. They have very good laboratory capacity in place at almost fixed cost up until something like 35k samples/year each valued at around £800-900 and even better at very high margin 75% plus. This is now ALL about securing more activities from existing and new clients. The bioscience market is a bit soft across the board at the moment, but the biomarker service is very unique and valued...so if we don't see real progress over the next 6 months or so, then sadly the team may need to be shaken up right from sales leadership up to CEO and/or CFO!
I think the main issue is communication. Yes we are only covering the debt, however, the Early CDT overheads are gone now too so lower CAPEX and there are contracts in place with Biodesix and Freenome that should guarantee some revenue for the coming years.
With focus on the ImmunoInsights Service I would wish to see some bolder statement as to the growth potential here. To say the pipe is growing by 0.75m every month standing at around 16-17m8o right now is not good enough. You need at least 4x coverage and probably more when the markets are still under pressure to deliver growth numbers. We need to see a big ambition here that gives investors trust in the companies' potential.
Sorry but we are currently at appx. 13.3mio market cap with real ImmunoInsights revenues at just over 1.1m or so
10x PE....management need to start playing ball here. Wtf
But I need to say it again. I am optimistic here and think that this focus will pay off. The next report will be an indicator. It better be good.
Remember this year is supposed to be the year of inflection for the company. At the moment it is the year for reflection for investors.
At this point it is hard to argue against what you are saying.
I think with the revenues from last report being so low the market has judged the market cap/ SP to be here. I know we sold part of biz off and have cash but it only covers the rest of the debt. What I can understand is a. the high costs (and we have to assume CEo salary etc is a big chunk) b. low revenues compared to what was forecasted (so I assume only a fraction of the facility is being used that was increased last year at a substantial cost) c. the lack of urgency.
I still believe that after being misled on revenues by so much the CFO has to be let go. The same for CEO, he may be great scientifically but that is very different to running a company, and a drop in SP from 250p to 18p says it all.
We need a change, someone to rescue the company and the low revenues. We have interest from big pharma companies and some recurring revenue, but we need to kick on, or we will be complaining for the next 5 years
Apparently the only way is down for this stock. :(
Yes, indeed a wise move by the CEO. I would be slightly surprised if we don't see more buys from chair, non-execs etc. If you genuinely believe in the business, then this is a very good top up price and it's always good the management team + board have meaningful personal skin in the game; over and above the options they have.
Goes without saying that the CEO buying in at these levels is an indication that at the very least he is confident in the value proposition of ONC.
Reasons for buying are obvious too:
-Shareholder trust
-Pharma M&A activity and ramp of shares before potential sale
-Knowing that this SP is rock bottom and can only go up from here
I trust that ONC has sold assets and not so desperate as to sell the rest for an apple and an egg
Thanks for your honesty Rooster.
Your average is pretty much the same as the very large holders, so I am very hopeful any silly bids will be bounced off!! It's also in the management team's interest.
You are spot on there. I would appeal to management/and the large investors to not sell out here at this valuation. Or anything under 120mio at its current state. Many people incuding myself would lose tremendous amounts and I would not see an immediate need to sell. There is opportunity to make so much more cash. My average on this SP is 1.3GBP with a proportionally gigantic holding.
I will have faith. That is all I have left. Faith and appeal
Worth a listen from 21:35:
https://www.linkedin.com/posts/paul-hill-a5994116_hot-stocks-on-vox-markets-activity-7070345511718805504-Px-j?utm_source=share&utm_medium=member_ios
For me - someone who believes in this business - the biggest risk of all is someone putting in a takeover bid, even at 100-200% of current share price, which will not be satisfactory for most holders, hopefully including large holders and the management team!!!
Apologies C_Schmitt, I inferred that from the ramper claims against Rooster and the bitterness shining through. Give it time then; this what to be expected from small companies: some make it, some don't - it's a journey. Good luck.
Ok Adam
Not sure where I stated that I sold at all, let alone at a loss …
C_schmitt; if you sold in panic, too bad. It's only a gain/loss when you sell.
In general don't trade in AIM or early stage companies unless you can afford lose everything! Simple.
I am also holding despite sitting on big paper losses. Why? Because I still have faith in the IP and its exploitation.
Rooster is not ramping. He is just hopeful we will see real positive resultsin the future. In any case, those who fall for empty ramping should not trade here or anywhere else.
Good luck on your journey C_Schmitt.
I am an average man who is facing the same facts as yourself. I am just looking at them through a more optimistic lens.
Faced with the facts as they are, I’m going to call it…
You’re a plant, either that or you are the CEO himself
Either way, ramping a duff stock like this can and does financially ruin people. It’s not fair
It's in everyone's interest that the business performs. Especially those running it as they are the most invested. I disagree with you.
This is not a short term investment. I think We will see this bird take off in the near term. My position is to keep holding until we are airborne and beyond.